For Immediate Release

Media Contact:
Steve DiMattia
(646) 695-2881
sdimattia@greentarget.com

Palmetto Medicare Now Covering Amniox Medical Products

NEOX® Wound Allograft Accessible to More than 27.6 Million Medicare Lives

ATLANTA, GA – April 13, 2016—AMNIOX Medical, Inc., a TissueTech, Inc. company, announced that Palmetto Medicare recently released its new Skin Substitute medical policy, effective May 17, 2016, covering NEOX® CORD 1K and NEOX® 100 wound allografts. The 3.6 million additional lives covered by Palmetto Medicare contribute to the more than 27.6 million lives with access to Amniox products, or more than 70 percent of lives covered by Medicare nationwide.

The policy change allows for skin substitute application procedures that are medically necessary and follow proper billing guidelines. Palmetto Medicare (Jurisdiction M) pays facility (Part A) and professional (Part B) claims for the states of North Carolina, South Carolina, West Virginia and Virginia.

Patients are covered for lower extremity neuropathic diabetic foot ulcers, venous stasis ulcers and full thickness skin loss ulcers that have failed standard of care therapy. These ulcers are characterized as partial and/or full-thickness ulcers that do not involve tendon, muscle, joint capsule or exposed bone.

Amniox parent, TissueTech, pioneered the clinical application of human umbilical cord and amniotic membrane to facilitate in adult wounds the rapid, scarless healing that occurs in utero. Since the company's inception, clinicians have performed more than 200,000 human transplants of its products and published more than 300 peer-reviewed studies supporting its technology platform. Amniox Medical was founded in 2011 to focus on the orthopedic and wound care markets.

"Palmetto has shown here an appreciation for what advocates shared with them at the Palmetto Open Forum meetings held in October 2015, which helped advance understanding of the clear benefits that our unique products offer," said Thomas J. Dugan, CEO of Amniox. "As the clinical evidence supporting Amniox tissue continues to expand, both providers and payers are looking to it as an important standard. Placental tissues have quickly become the most commonly used advanced tissue therapy for chronic wounds and payers are recognizing this."

In utero, wound healing occurs rapidly and with minimal scar. This restorative ability is innate to placental tissues, including umbilical cord and amniotic membrane. Heavy chain hyaluronic acid/pentraxin-3 is the key protein complex present in these tissues to orchestrate the healing process. Amniox Medical is the first provider of a human tissue allograft composed of both umbilical cord and amniotic membrane. Amniox utilizes its proprietary CryoTek™ process, a cryopreservation technology, to preserve the biological and structural integrity of the native tissue and published studies have demonstrated that the CryoTek process more effectively preserves the structural and biological integrity of the tissue.

About Amniox Medical, Inc.

Founded in 2011 to serve the orthopedic and wound care markets, Amniox Medical is dedicated to developing and marketing regenerative therapies processed from umbilical cord and amniotic membrane utilizing its proprietary CryoTek technology. This process has been proven to preserve the innate

biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. Amniox Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products. For additional information, please visit http://www.amnioxmedical.com

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue®, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; BioTissue develops and markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) have supported TissueTech's research with more than 25 continuous years of research grants. Since the company's inception, clinicians have performed more than 200,000 human implants of the company's products and published more than 300 peer-reviewed studies supporting its technology platform. The Company's first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.

###